ArticleBalkan journal of medical genetics : BJMG2025
Novel Mutation of
Article in Balkan journal of medical genetics : BJMG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a monogenic cerebral small-vessel disease characterized by migraine, recurrent ischemic strokes, psychiatric disorder, and progressive cognitive decline. CADASIL is a cerebrovascular disease closely related to the Objective: To investigate the phenotypic features and causative gene in a Chinese patient with CADASIL. Material and Methods: This is a multi-generation family with CADASIL. The brain computed tomography (CT) and magnetic resonance imaging (MRI) were performed for the proband and other affected family members. DNA samples were screened for gene mutation by whole exome sequencing (WES), and potential pathogenic mutations were validated by Sanger sequencing. Results: One novel heterozygous frameshift mutation, c.5171_5172delCA, p. (Thr1724fs17), in the Conclusions: The novel pathogenic frameshift mutation, c.5171_5172delCA, p. (Thr1724fs17), in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.